Results 11 to 20 of about 58,483 (238)
Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System
Viruses, 2015 Retroviral protease inhibitors (PIs) are fundamental pillars in the treatment of HIV infection and acquired immunodeficiency syndrome (AIDS). Currently used PIs are designed against HIV-1, and their effect on HIV-2 is understudied.
Mohamed Mahdi +3 more
doaj +1 more source
A modular system to evaluate the efficacy of protease inhibitors against HIV-2.
PLoS ONE, 2014 The human immunodeficiency virus (HIV) protease is a homodimeric aspartyl protease that is crucial for the viral life-cycle, cleaving proviral polyproteins, hence creating mature protein components that are required for the formation of an infectious ...
Mohamed Mahdi +3 more
doaj +1 more source
HIV protease inhibitors and obesity [PDF]
Current Opinion in Endocrinology, Diabetes and Obesity, 2010 To review the current scientific literature and recent clinical trials on HIV protease inhibitors and their potential role in the pathogenesis of lipodystrophy and metabolic disorders.HIV protease inhibitor treatment may affect the normal stimulatory effect of insulin on glucose and fat storage.
Erdembileg, Anuurad +2 more
openaire +2 more sources
Universitas Scientiarum, 2019 The HIV-1 protease plays an essential role in the replication cycle of HIV-1; therefore there is a direct need to develop novel inhibitors of the HIV-1 protease, which can cease the viral replication.
Ammara Akhtar, Waqar Hussain, Nouman Rasool3
doaj +1 more source
Proteochemometric modeling of HIV protease susceptibility
BMC Bioinformatics, 2008 Background A major obstacle in treatment of HIV is the ability of the virus to mutate rapidly into drug-resistant variants. A method for predicting the susceptibility of mutated HIV strains to antiviral agents would provide substantial clinical benefit ...
Prusis Peteris +4 more
doaj +1 more source
BMC Cancer, 2021 Background The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increase ...
Alison K. Yoder +10 more
doaj +1 more source
Comparing the Performance of Molecular Docking Tools for HIV-1 Protease Inhibitors
Journal of Advanced Engineering and Computation, 2023 Human immunodeficiency virus (HIV) continues to pose a significant public health threat worldwide, disproportionately affecting marginalized and vulnerable populations despite advancements in prevention and treatment.
Han Thi Ngoc Pham, Huong Thi Thu Phung
doaj +1 more source
Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease
Biology, 2012 Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and ...
Ladislau C. Kovari +6 more
doaj +1 more source
Molecular Basis for Drug Resistance in HIV-1 Protease
Viruses, 2010 HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer +12 more
doaj +1 more source
A folding inhibitor of the HIV‐1 protease [PDF]
Proteins: Structure, Function, and Bioinformatics, 2005 AbstractBecause the human immunodeficiency virus type 1 protease (HIV‐1‐PR) is an essential enzyme in the viral life cycle, its inhibition can control AIDS. The folding of single‐domain proteins, like each of the monomers forming the HIV‐1‐PR homodimer, is controlled by local elementary structures (LES, folding units stabilized by strongly interacting,
R. A. Broglia +5 more
openaire +4 more sources